Belite Bio Inc

Research Belite Bio Inc (BLTE) on Bullrun: market cap USD 6.20B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBLTE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 6.20B
• Financial periodFY2025
• Net income-USD 77.61M
• Free cash flow-USD 37.06M

Valuation Snapshot

latest market cap is USD 6.20B.

About Belite Bio Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Frequently asked questions

What is Belite Bio Inc's market cap?

Belite Bio Inc's market capitalization is USD 6.20B.

What does Belite Bio Inc do?

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.